Revised SPC: Rizmoic (nalmedene) tablets

SPC now warns that nalmedene shouldn't be used in patients with known or suspected GI obstruction, GI perforation or any condition which might result in impaired integrity of the GI tract wall, as there have been reports of fatal GI perforations in the post-marketing setting.

Source:

electronic Medicines compendium